Sanctuary Advisors LLC Takes $918,000 Position in United Therapeutics Corporation $UTHR

Sanctuary Advisors LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,695 shares of the biotechnology company’s stock, valued at approximately $918,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Torren Management LLC bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the fourth quarter worth $31,000. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on UTHR shares. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Trading Up 2.2%

NASDAQ UTHR opened at $527.91 on Friday. The company has a market cap of $22.64 billion, a P/E ratio of 18.89, a PEG ratio of 1.75 and a beta of 0.59. The company has a fifty day simple moving average of $530.89 and a 200 day simple moving average of $538.86. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the company posted $6.41 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insider Activity

In related news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at $23,631,280.08. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total value of $4,914,160.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $167,827,875.04. This trade represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 424,075 shares of company stock valued at $227,336,485. 8.60% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.